Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

Loyola University forms new institute for molecular level disease research

Loyola University Chicago Stritch School of Medicine has formed a new research institute dedicated to understanding the molecular causes of cancer, autoimmune disorders, cardiovascular disease and several other illnesses.

10 Aug 2010

Amarin completes enrollment in AMR101 Phase 3 MARINE clinical trial

Amarin Corporation plc, a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that its MARINE trial, a Phase 3 clinical trial of AMR101, has completed patient enrollment and randomization into the treatment phase of this trial. The Company indicated that top line results from this trial are expected early in 2011, towards the early part of the range of guidance provided previously.

10 Aug 2010

Scientists suggest daily intake of vitamin D helps to reduce disease frequency

Anthony Norman, a leading international expert in vitamin D, proposes worldwide policy changes regarding people's vitamin D daily intake amount in order to maximize the vitamin's contribution to reducing the frequency of many diseases, including childhood rickets, adult osteomalacia, cancer, autoimmune type-1 diabetes, hypertension, cardiovascular disease, obesity and muscle weakness.

10 Aug 2010

UCLA study identifies neurocognitive pathways involved in inflammatory responses to acute social stress

Everyone experiences social stress, whether it is nervousness over a job interview, difficulty meeting people at parties, or angst over giving a speech. In a new report, UCLA researchers have discovered that how your brain responds to social stressors can influence the body's immune system in ways that may negatively affect health.

10 Aug 2010

Vanguard to acquire assets of Arizona Heart Hospital

MedCath Corporation, and its physician partners jointly announced today they have entered into a definitive agreement for Vanguard Health Systems to acquire substantially all the assets of Arizona Heart Hospital. The transaction is expected to close during MedCath's first quarter of fiscal 2011, which ends on December 31, 2010, subject to certain closing conditions.

9 Aug 2010

Researchers examine differences in eating habits of African Americans

7 Aug 2010

Medtronic completes enrollment in Complete SE vascular stent superficial femoral artery clinical study

With an expanded focus on addressing peripheral arterial disease (PAD), Medtronic, Inc. (NYSE: MDT), today announced that it has completed enrollment in a clinical trial of the company's Complete SE (self-expanding) vascular stent for the treatment of atherosclerosis in the superficial femoral artery (SFA), including the proximal popliteal artery (PPA), which runs under the skin of the thigh.

7 Aug 2010

Survey reveals need for nutrition education among African Americans for disease prevention, management

Researchers looking for differences in eating habits of African Americans based on whether or not they had Type 2 diabetes uncovered an unexpected result: No matter what the blood sugar level was, the dietary intakes were pretty much the same.African Americans are 1.8 times more likely to develop Type 2 diabetes and 1.4 times more likely to be obese than are non-Hispanic whites, according to federal health agencies. Obesity is a leading risk factor for development of diabetes, a condition that results when the body cannot properly use insulin to transfer sugar from the blood to muscle and fat cells that use glucose for energy.

6 Aug 2010

Alnylam publishes research findings of Sort1 gene role in cardiovascular disease development

Alnylam Pharmaceuticals, Inc. a leading RNAi therapeutics company, announced today the publication of new research findings in the journal Nature describing the discovery and validation of the role of the gene Sort1 in the development of cardiovascular disease, including myocardial infarction (MI). This work was done with collaborators at University of Pennsylvania (UPenn) School of Medicine, Massachusetts General Hospital (MGH), and the Broad Institute. The collaborative effort combined genome-wide association studies (GWAS) and RNAi technology to identify and validate novel genes as targets for new therapies for heart disease.

6 Aug 2010

Scientists find new way to make beating heart cells from body's own cells

Scientists at the Gladstone Institute of Cardiovascular Disease have found a new way to make beating heart cells from the body's own cells that could help regenerate damaged hearts. Over 5 million Americans suffer from heart failure because the heart has virtually no ability to repair itself after a heart attack.

6 Aug 2010

Diabetes Self-Management Training helps to prevent complications in pre diabetes patients

Citing research that demonstrates the cost savings and health benefits of providing Diabetes Self-Management Training (DSMT) to patients with pre-diabetes, the American Association of Diabetes Educators today called on private insurers and Medicare to include education as a covered benefit for this population.

5 Aug 2010

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Merck reported that two pivotal Phase III registration studies for boceprevir, its investigational oral hepatitis C protease inhibitor, have been completed and met the primary endpoints: in both studies in patients with chronic hepatitis C virus (HCV) genotype 1 infection, the addition of boceprevir to treatment with PEGINTRON® and REBETOL® significantly increased the number of patients who achieved sustained virologic response, compared to control groups that received Peg/riba plus placebo.

5 Aug 2010

Genzyme, Isis announce results of two mipomersen phase 3 studies

Genzyme Corp. and Isis Pharmaceuticals Inc. today announced results of two phase 3 studies of mipomersen in patients who had high cholesterol levels while on maximally tolerated lipid-lowering therapy. In the study of patients with severe hypercholesterolemia, mipomersen reduced LDL-C, the primary endpoint, by 36 percent compared with a 13 percent increase for placebo.

5 Aug 2010

Sigma-Aldrich, NHLBI and BU collaborate in atherosclerotic cardiovascular disease research

Sigma-Aldrich® today announced it has entered into an agreement with the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health, and Boston University (BU) to develop methods to measure several potential biomarkers of atherosclerotic cardiovascular disease (CVD) using plasma samples from the NHLBI's Framingham Heart Study (FHS), one of the most prestigious clinical studies in medicine. Funding for the project is provided by the NHLBI to Sigma-Aldrich under a research subaward agreement with BU.

5 Aug 2010

SORT1 pathway holds promise as new target for therapeutic intervention for LDL cholesterol reduction

The true power of genomic research lies in its ability to help scientists understand biological processes, particularly those that - when altered - can lead to disease. This power is demonstrated dramatically in a pair of papers published today in the journal Nature. In the first, a global team of researchers describes 95 different variations across the genome that contribute in different degrees to alterations in blood cholesterol and triglyceride levels in multiple human populations. In the second report, close examination of just one of these common variants not only reveals the involvement of an unexpected genetic pathway in lipid metabolism but also provides a blueprint for using genomic findings to unravel biological connections between lipid levels and coronary heart disease.

5 Aug 2010

Cardiogenesis second-quarter 2010 revenue increases 9% to $2.43 million

Cardiogenesis Corporation, a leading developer of surgical products used to treat cardiac patients suffering from severe angina, today reported financial results for its second quarter and first half ended June 30, 2010.

5 Aug 2010

FDA designates XOMA 052 orphan drug for Behcet's disease

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that the U.S. Food and Drug Administration has designated XOMA 052, an antibody to interleukin-1 beta, an orphan drug for the treatment of Behcet's disease. As previously announced, the Committee for Orphan Medical Products of the European Medicines Agency has recommended the granting of orphan medicinal product designation for XOMA 052 for the same indication in the European Union.

5 Aug 2010

Celera decreases second-quarter net loss to $6.1 million

Celera Corporation today reported net revenues of $32.6 million for the second quarter of 2010 that ended June 26, 2010, compared to $41.4 million for the prior year quarter. For the second quarter of 2010, Celera reported a net loss of $6.1 million, or $0.07 per share, compared to a net loss of $31.7 million, or $0.39 per share, for the prior year quarter.

4 Aug 2010

POZEN reports $16.2M net income for second-quarter 2010

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced results for the second quarter ended June 30, 2010.

3 Aug 2010

Toxic protein in bee venom improves liposome encapsulated drug effectiveness

The next time you are stung by a bee, here's some consolation: a toxic protein in bee venom, when altered, significantly improves the effectiveness liposome-encapsulated drugs or dyes, such as those already used to treat or diagnose cancer. This research, described in the August 2010 print issue of the FASEB Journal, shows how modified melittin may revolutionize treatments for cancer and perhaps other conditions, such as arthritis, cardiovascular disease, and serious infections.

3 Aug 2010

Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

Loyola University forms new institute for molecular level disease research

Amarin completes enrollment in AMR101 Phase 3 MARINE clinical trial

Scientists suggest daily intake of vitamin D helps to reduce disease frequency

UCLA study identifies neurocognitive pathways involved in inflammatory responses to acute social stress

Vanguard to acquire assets of Arizona Heart Hospital

Researchers examine differences in eating habits of African Americans

Medtronic completes enrollment in Complete SE vascular stent superficial femoral artery clinical study

Survey reveals need for nutrition education among African Americans for disease prevention, management

Alnylam publishes research findings of Sort1 gene role in cardiovascular disease development

Scientists find new way to make beating heart cells from body's own cells

Diabetes Self-Management Training helps to prevent complications in pre diabetes patients

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Genzyme, Isis announce results of two mipomersen phase 3 studies

Sigma-Aldrich, NHLBI and BU collaborate in atherosclerotic cardiovascular disease research

SORT1 pathway holds promise as new target for therapeutic intervention for LDL cholesterol reduction

Cardiogenesis second-quarter 2010 revenue increases 9% to $2.43 million

FDA designates XOMA 052 orphan drug for Behcet's disease

Celera decreases second-quarter net loss to $6.1 million

POZEN reports $16.2M net income for second-quarter 2010

Toxic protein in bee venom improves liposome encapsulated drug effectiveness

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in